Gelteq Ltd

GELS

Market cap $5.5M

2025 Non-GAAP Net Income Totaled $162,000 or $0.02 Per Share Record Results Driven by Fifth Sequential Quarter of Record-Setting Revenues, with the Momentum Setting Stage for Another Year of Double-Digit Growth LAS VEGAS, NV / ACCESS Newswire / April 8, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported audited results for the year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.

Strong Annual Results Driven by Record-Setting Revenues for Fifth Quarter in a Row, Setting Stage for Another Record Year in 2026   LAS VEGAS, NV / ACCESS Newswire / April 2, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported preliminary unaudited results for year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.

MELBOURNE, Australia and LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) and Healthy Extracts™ Inc. (“Healthy Extracts”) today announced the signing of a Memorandum of Understanding (“MoU”) formalising a strategic partnership designed to accelerate the commercial rollout of next-generation gel-based nutraceutical products. The collaboration builds on Healthy Extracts' prior purchases of Gelteq-formulated products and marks the first phase of a long-term plan to bring Gelteq's proprietary gel delivery technology to large-scale US manufacturing and global distribution.

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company's proprietary oral gel platform. The findings demonstrate that Gelteq's platform significantly enhances the absorption and bioavailability of cannabidiol (“CBD”) compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform's potential to change how medicinal cannabis is delivered and experienced by patients.

Collaboration Combines Growing International Interest in Gelteq's Sports Science Technology with Rising Interest in Flag Football Ahead of 2028 Summer Olympic Games Debut in Los Angeles Collaboration Combines Growing International Interest in Gelteq's Sports Science Technology with Rising Interest in Flag Football Ahead of 2028 Summer Olympic Games Debut in Los Angeles

Agreement includes minimum annual order commitments totalling approximately USD $1.3 million Agreement includes minimum annual order commitments totalling approximately USD $1.3 million

MELBOURNE, Australia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced preclinical findings demonstrating the effectiveness, flexibility, and safety profile of its proprietary gel platform. The results address a major challenge in pharmaceutical development and demonstrate that Gelteq's technology can enhance the oral delivery of oil-soluble and poorly soluble drugs.

MELBOURNE, Australia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (Nasdaq: GELS) (“Gelteq”) today announced that Nathan Givoni, its Chief Executive Officer, will present at the Q4 Investor Summit Virtual on December 9, 2025, where he will share updates on Gelteq's growth strategy, market positioning, and upcoming catalysts. The Investor Summit is an exclusive virtual event connecting investors with disruptive small and microcap companies.

Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug Classes Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug Classes

LAS VEGAS, NV / ACCESS Newswire / November 14, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in plant-based nutraceutical innovations, reported results for the third quarter and nine months ended September 30, 2025. All comparisons are to the same year-ago period unless otherwise noted.